Célia Dupain, Tom Gutman, Elodie Girard, Choumouss Kamoun, Grégoire Marret, Zahra Castel-Ajgal, Marie-Paule Sablin, Cindy Neuzillet, Edith Borcoman, Ségolène Hescot, Céline Callens, Olfa Trabelsi-Grati, Samia Melaabi, Roseline Vibert, Samantha Antonio, Coralie Franck, Michèle Galut, Isabelle Guillou, Maral Halladjian, Yves Allory, Joanna Cyrta, Julien Romejon, Eleonore Frouin, Dominique Stoppa-Lyonnet, Jennifer Wong, Christophe Le Tourneau, Ivan Bièche, Nicolas Servant, Maud Kamal, Julien Masliah-Planchon
BACKGROUND: High tumor mutational burden (TMB) was reported to predict the efficacy of immune checkpoint inhibitors (ICIs). Pembrolizumab, an anti-PD-1, received FDA-approval for the treatment of unresectable/metastatic tumors with high TMB as determined by the FoundationOne®CDx test. It remains to be determined how TMB can also be calculated using other tests. RESULTS: FFPE/frozen tumor samples from various origins were sequenced in the frame of the Institut Curie (IC) Molecular Tumor Board using an in-house next-generation sequencing (NGS) panel...
February 20, 2024: BMC Biology